Trump administration intervenes after “Dilbert” creator’s plea to speed Pluvicto prostate cancer treatment
Following Scott Adams’s public plea, the Trump administration intervened to expedite his FDA-cleared Pluvicto prostate cancer treatment after scheduling delays at Kaiser, highlighting access challenges for newly approved therapies and the influence of high-profile appeals on care timelines.
Key takeaways
- Scott Adams said Kaiser Permanente of Northern California approved his request for Pluvicto but had not scheduled the procedure — reporting attributed to STAT News.
- Adams posted an urgent plea on X asking former President Donald Trump for help; the post said expedited scheduling could give him “a fighting chance” (Fox News).
- President Trump and senior aides — including HHS Secretary Robert F. Kennedy Jr., White House deputy chief of staff Dan Scavino, and Dr. Mehmet Oz — publicly and privately signaled immediate involvement to resolve the delay (STAT News; Fox News).
- Pluvicto, a PSMA-targeted radioligand therapy, had its FDA indication expanded in March to an earlier stage of metastatic prostate cancer, increasing eligibility for patients like Adams (STAT News).
Administration response and timeline
Adams posted that Kaiser had approved his request for Pluvicto but had not scheduled the radioligand therapy. His social post went viral and drew attention from the former president and senior officials, according to reporting by STAT News.
“On it!” — President Trump’s public reply, per news reports.
Reports say President Trump contacted Centers for Medicare and Medicaid Administrator Mehmet Oz, who then engaged both Adams and Kaiser representatives. Dr. Oz and administration contacts reportedly pressed for rapid scheduling to give Adams a chance at treatment (STAT News).
HHS Secretary Robert F. Kennedy Jr. responded directly on social media saying, “The President wants to help,” and asked how to reach Adams. White House deputy chief of staff Dan Scavino posted that Trump, RFK Jr., and Dr. Oz were “all tracking now,” indicating high-level coordination to resolve the scheduling problem quickly (Fox News; STAT News).
What Pluvicto is and why timing matters
Pluvicto is a radioligand therapy that targets prostate-specific membrane antigen (PSMA) on prostate cancer cells. The FDA expanded the drug’s approval in March to an earlier stage of metastatic disease, broadening eligibility for many patients (STAT News).
Timing can be critical: for patients with advancing prostate cancer, delays may reduce the chance to benefit. Adams described ongoing pain and rapid decline since his diagnosis and characterized Pluvicto as “not a cure, but it does give good results to many people,” underscoring that scheduling delays may imperil outcomes (Fox News).
Adams’s public medical account and prior treatments
Adams has been public about his diagnosis and previous treatments. He reported trying off-label or alternative remedies—such as ivermectin and fenbendazole—which he said did not help. His updates framed the Pluvicto delay as a life-or-death timing issue in need of urgent resolution (STAT News).
Adams’s public profile and long-standing support for Trump likely amplified the reach of his plea and may have influenced the speed of the response (STAT News).
Kaiser and official confirmations
Kaiser Permanente had not issued a public statement about the scheduling delay or the outreach by the former president and administration officials as of reporting. Likewise, neither the White House nor HHS posted a formal public announcement detailing next steps after the social media exchanges (STAT News).
Media coverage and public reaction
The story drew national coverage across outlets including STAT News, Fox News, The Epoch Times, and AOL. Reporting emphasized both the human urgency and broader access questions for newly approved therapies.
Critics and questions about equity
Observers raised equity concerns: if public appeals and high-profile connections can speed access, what happens to ordinary patients without platforms or political ties? Critics warn that ad hoc interventions cannot replace systemwide fixes to ensure fair, timely access for all eligible patients.
Healthcare experts point to bottlenecks in scheduling, specialty equipment, and coordination between insurers, hospitals, and treatment centers as root causes that require structural solutions (STAT News).
Why patients still face delays after FDA approval
FDA approval clears a drug for use, but real-world access depends on insurer authorizations, hospital capacity, trained staff, and complex logistics—especially for radioligand therapies. These administrative and operational hurdles can delay treatment delivery even after approval (STAT News).
Implications for the United States
Economic and system impacts: The Adams episode underscores gaps in U.S. healthcare delivery — costly, resource-intensive oncology treatments, staffing shortages, constrained radiology and nuclear medicine capacity, and prior-authorization delays all shape access (STAT News).
Political consequences: Supporters may view the administration’s rapid response as decisive action to cut red tape. Critics question whether political connections should influence access to care (Fox News).
Social effects: The case may encourage others to use public platforms to seek help, potentially improving outcomes for some but risking a two-tiered system where visibility equals access. Patient groups may push for clearer timelines and safeguards so all eligible patients receive timely care (STAT News).
Practical applications for patients and providers
Patients awaiting newly approved therapies should document approvals, maintain clear records of prior authorizations, and escalate through insurer or provider patient advocates if scheduling stalls. Providers and health systems should review internal workflows to prevent critical delays for time-sensitive candidates for targeted therapies like Pluvicto (STAT News).
Reporting notes and sources
This article draws on reporting from: STAT News; Fox News; The Epoch Times; and AOL. As of reporting, Kaiser Permanente had not issued a public comment on the scheduling matter (STAT News).
Note: The exchange underscores an individual emergency and broader policy questions about equitable access to newly approved cancer treatments; developments in the coming days may show whether this intervention yields a prompt appointment for Adams and whether it prompts broader changes.
